For decades, federal law required an in-person medical evaluation before a clinician could prescribe controlled substances like Adderall, Xanax, or opioid pain medication. The pandemic forced the DEA to temporarily waive that rule, opening the door to telehealth prescribing of controlled substances on a scale never seen before. Millions of Americans received a controlled substance prescription through telehealth during the pandemic era. Now the DEA telemedicine rules that matter most concern what happens as those temporary flexibilities are worked into permanent policy. The outcome will shape whether millions of patients can continue accessing ADHD medications, anxiety treatments, and addiction therapy through their screens – or must return to in-person visits. For an overview of how telehealth works across conditions and platforms, our telehealth guide provides the foundation, and our healthcare policy guide covers the broader regulatory landscape.
The short version: Since the pandemic, the DEA and HHS have let clinicians prescribe controlled substances by telehealth without a prior in-person visit. Rather than ending, these flexibilities have been extended again and again – most recently, a fourth temporary extension published at the end of 2025 carries them through December 31, 2026 – while regulators finalize permanent rules. A proposed “special registration” framework exists but is not yet final, and buprenorphine for opioid use disorder has generally been treated more favorably than ADHD stimulants or opioids for pain. Because these deadlines keep moving, treat any date as provisional and confirm the current rules with the DEA or your prescriber. This is general information, not legal or medical advice.
The Ryan Haight Act: Why These Rules Exist
The Ryan Haight Online Pharmacy Consumer Protection Act of 2008 was passed after an 18-year-old in California died from an overdose of drugs purchased from an online pharmacy that prescribed opioids without ever seeing him in person. The law established a clear rule: a practitioner must conduct at least one in-person medical evaluation before prescribing a controlled substance via the internet.
The law included a narrow telemedicine exception, but it required a special DEA registration process that was never fully implemented. For more than a decade, the exception existed on paper but was essentially unusable in practice. This meant controlled substances generally could not be legally prescribed via telehealth under normal circumstances, creating a significant barrier for patients in rural areas, those with mobility limitations, and anyone who struggled to access in-person psychiatric or pain-management care.
When COVID-19 arrived in March 2020, the DEA activated its public-health-emergency authority to temporarily suspend the in-person requirement for all controlled substance schedules. This single regulatory action unlocked telehealth prescribing for the most commonly needed controlled medications and transformed how millions of Americans received treatment for ADHD, anxiety, chronic pain, and opioid use disorder.
What the DEA Changed During the Pandemic
From March 2020 through the end of the declared public health emergency in May 2023, the DEA allowed any DEA-registered practitioner to prescribe controlled substances via telehealth without an in-person exam. No special registration was needed. The only requirement was that the prescriber held a valid DEA registration and an appropriate state license where the patient was located.
The impact was enormous. Telehealth prescribing of Schedule II stimulants (like Adderall, Vyvanse, and Ritalin for ADHD) rose sharply during this period, and adult ADHD diagnoses surged as telehealth removed access barriers that had previously prevented many adults from seeking evaluation. Platforms like Done, Cerebral, and others built entire business models around telehealth ADHD diagnosis and treatment. If you are comparing stimulant options, our overview of Adderall versus Ritalin explains how these medications differ.
Buprenorphine prescribing for opioid use disorder treatment via telehealth also surged, and research has generally suggested that telehealth buprenorphine patients had comparable or better retention in treatment than in-person patients. This finding matters because opioid use disorder treatment is time-sensitive – patients who face barriers to access are at higher risk of relapse and overdose death.
The pandemic period also revealed concerns. Some telehealth platforms were accused of prescribing stimulants and other controlled substances with minimal clinical evaluation, fueling worries about diversion and misuse. Several companies faced regulatory scrutiny, and reports of stimulant shortages raised questions about whether telehealth was driving over-prescribing. These concerns directly shaped the regulatory framework that followed.
The Current DEA Telemedicine Framework
After multiple rounds of proposed rules, public-comment periods that generated tens of thousands of comments, and repeated deadline extensions, the picture as of early 2026 is best described as a temporary bridge while permanent rules are finalized. Rather than let the flexibilities expire, the DEA – jointly with the Department of Health and Human Services – has issued a series of temporary extensions.
The most recent of these, a fourth temporary extension published at the end of December 2025, continues the pandemic-era telemedicine flexibilities through December 31, 2026. In practical terms, that means many clinicians can, for now, continue prescribing controlled substances via telehealth without a prior in-person visit. However, this is a moving target: the deadline has already shifted several times, and a future administration or final rulemaking could change it. Verify the current status directly with the DEA or your prescriber before relying on any specific date.
A proposed “special registration” framework
In January 2025, the DEA proposed a long-awaited framework – “Special Registrations for Telemedicine and Limited State Telemedicine Registrations” – intended to create a permanent pathway for qualifying clinicians to prescribe controlled substances via telemedicine, with safeguards designed to limit diversion. As of early 2026, this remains a proposed rule; it has not been finalized, and the details could change before (or if) it takes effect. Until a permanent framework is in place, the temporary extensions are what keep telehealth prescribing available.
Buprenorphine for opioid use disorder
Buprenorphine has generally received more favorable treatment than other controlled substances because restricting access can directly lead to overdose deaths. In January 2025, the DEA issued a final rule addressing the expansion of buprenorphine treatment via telemedicine – including provisions for prescribing an initial supply based on a telemedicine (in some cases audio-only) encounter and a review of prescription drug monitoring data – though its effective date was subsequently delayed alongside related rulemaking. The overall direction has been to preserve telehealth access to this life-saving medication.
Schedule II stimulants (ADHD medications)
Stimulants such as Adderall, Vyvanse, Ritalin, and Concerta remain the most scrutinized category for telehealth prescribing. Proposed permanent rules have contemplated guardrails – such as expectations around in-person evaluation at some point in the course of treatment and additional recordkeeping – but the specifics have shifted across drafts and are not settled. In the meantime, the temporary extension allows continued telehealth prescribing, and many platforms have voluntarily built in-person touchpoints into their care models.
Opioids for pain
New opioid prescriptions for pain management have consistently been treated as the highest-risk category for telehealth. Even under the flexibilities, clinicians and platforms tend to be conservative here, and permanent rules are widely expected to keep opioid-for-pain prescribing more tightly controlled than other categories.
What This Means for Patients
If you currently receive a controlled substance prescription through telehealth, here is a general sense of what to expect – keeping in mind that the rules can change and vary by state:
ADHD patients: You may be able to initiate or continue stimulant treatment via telehealth for now, but you should expect that an in-person evaluation could be required at some point as permanent rules take shape. Platforms such as Done, Cerebral, and ADHD Online have adjusted their models, often partnering with local clinics, urgent care centers, or primary care practices for a qualifying visit. Some platforms help coordinate this in-person visit; others leave it to the patient. Ask your platform specifically how they handle any in-person requirement and what would happen to your prescription if the rules change.
Patients on buprenorphine/Suboxone: Access has generally been preserved. The bipartisan Mainstreaming Addiction Treatment (MAT) Act eliminated the separate DEA waiver (“X-waiver”) requirement for prescribing buprenorphine, and telehealth prescribing of buprenorphine has generally remained available. Many addiction-treatment telehealth providers can continue prescribing with telehealth-friendly requirements, though details vary by state and clinical circumstances.
Anxiety and sleep-medication patients: Benzodiazepines (like Xanax, Klonopin, Ativan) and certain sleep medications (like zolpidem) fall under different schedules, and their telehealth prescribing practices vary. Many telehealth providers have shifted away from benzodiazepines in favor of non-controlled alternatives (SSRIs, SNRIs, buspirone, hydroxyzine) that can be prescribed without the same regulatory sensitivities. If you currently receive a benzodiazepine through telehealth, discuss your provider’s compliance with the current rules.
For more on how these changes affect telehealth costs and insurance coverage, our healthcare costs guide covers cost considerations across different care models.
How Telehealth Platforms Have Adapted
The evolving DEA rules have pushed telehealth companies to rethink their business models. Several platforms that built their businesses on telehealth-only controlled substance prescribing have shifted significantly:
ADHD-focused platforms: Companies such as Cerebral, Done, and Ahead have moved toward partnerships with in-person clinics or hybrid models where an evaluation can be conducted in person with subsequent follow-ups virtual. After earlier regulatory scrutiny, several implemented more conservative prescribing protocols and added compliance staff.
Opioid use disorder treatment platforms: Providers such as Bicycle Health, Workit Health, and Eleanor Health have largely maintained telehealth access for buprenorphine prescribing, given the more favorable regulatory treatment of addiction medications, and have been vocal advocates for preserving telehealth access for substance-use treatment.
Major insurer-backed platforms: MDLIVE, Teladoc, and Optum Virtual Care have generally been more conservative about controlled substance prescribing and have largely operated within tighter guardrails from the start, often referring patients to in-network psychiatrists for controlled substance management rather than prescribing through on-demand urgent-care services.
The market has also seen entrants that specialize in a hybrid telehealth-plus-in-person model – offering initial in-person evaluations with ongoing telehealth management. This approach may represent a durable equilibrium for controlled substance prescribing via telehealth, whatever the final federal rules look like.
State-Level Variation
DEA rules set the federal floor, but states can impose stricter requirements. Some states require an in-person visit before any controlled substance can be prescribed via telehealth, regardless of the DEA’s position. Others have adopted more permissive approaches that align with or exceed federal flexibility.
Because state policies change, it is best not to assume any particular state is “strict” or “permissive” without checking current rules. The patchwork of state regulations creates real complexity for patients who travel or relocate, and for telehealth platforms that operate nationally.
Before relying on telehealth for controlled substance prescriptions, check your state medical board’s telemedicine prescribing rules. Your telehealth platform should also flag any state-specific requirements during intake. The Federation of State Medical Boards (FSMB) maintains a regularly updated resource on state telehealth policies that patients and providers can reference.
The Broader Policy Debate
The DEA’s telemedicine rulemaking has sparked a broader debate about how to balance access, safety, and innovation in healthcare. Patient-advocacy organizations, mental-health groups, and telehealth companies argue that in-person requirements create unnecessary barriers to care, particularly for patients in rural areas, those with disabilities, and people with conditions (like severe anxiety or agoraphobia) that make in-person visits especially difficult.
On the other side, the DEA, some medical societies, and addiction-medicine experts point to evidence of over-prescribing during the pandemic era, stimulant shortages that affected patients with legitimate prescriptions, and the potential for telehealth-based “pill mills” that prioritize volume over clinical appropriateness.
The compromise that appears to be emerging – broad telehealth access paired with some form of special registration and, for higher-risk drugs, eventual in-person verification – satisfies neither camp entirely but may represent a workable middle ground. Congressional interest in permanent telehealth rules for controlled substances remains high, with multiple bills introduced that would codify various approaches.
Frequently Asked Questions
Can a telehealth doctor prescribe Adderall?
For now, under the current temporary flexibilities, a telehealth provider can prescribe stimulants like Adderall after a clinical evaluation. Permanent rules may add expectations around an in-person visit at some point in treatment. Because requirements vary by state and are still being finalized, ask your provider what steps you need to take to start and keep your prescription, and verify the current status of the federal rules.
Can I get Xanax through telehealth?
Some telehealth providers can prescribe benzodiazepines like Xanax, but many are cautious due to abuse potential, regulatory scrutiny, and clinical guidelines that recommend non-benzodiazepine alternatives as first-line treatment for anxiety. Your provider may recommend SSRIs, SNRIs, buspirone, or hydroxyzine before considering a benzodiazepine. If a benzodiazepine is clinically appropriate, the prescribing practices depend on the drug’s schedule and your state’s regulations.
Do the DEA telemedicine rules affect Suboxone prescribing?
Buprenorphine-based medications like Suboxone have received more favorable treatment in the DEA’s telemedicine approach. The MAT Act eliminated the separate waiver requirement for prescribing buprenorphine, and many patients can continue receiving buprenorphine prescriptions through telehealth. Specific requirements vary by state and clinical circumstances, so confirm the details with your provider.
Are the DEA telemedicine rules permanent?
Not yet. As of early 2026, the flexibilities are being extended on a temporary basis – most recently through December 31, 2026 – while the DEA works toward permanent rules, including a proposed special-registration framework that has not been finalized. The situation continues to evolve, so stay in contact with your prescribing provider about any changes that may affect your treatment, and verify the current rules with the DEA.
What happens if my telehealth provider can’t prescribe my medication anymore?
If regulatory changes affect your telehealth provider’s ability to prescribe your medication, they should help you transition to a compliant arrangement. This might mean completing an in-person visit to continue telehealth prescribing, transferring your care to a local in-person provider, or switching to a non-controlled alternative medication. Never stop a controlled medication abruptly without medical guidance, because abrupt discontinuation of some medications can be dangerous.
Is this legal advice?
No. This article is general educational information about a policy area that is changing quickly. It is not legal advice or medical advice. For guidance about your specific medications, your prescriber is the right source; for questions about legal compliance, consult a qualified attorney, and check the DEA’s official resources for the latest rules.
What to Do Next
If you receive controlled substance prescriptions through telehealth, confirm with your provider that they are following current DEA rules and ask specifically what steps you may need to take to maintain your prescription. Find out whether you will need an in-person visit and what the timeline is. If you are starting a new controlled substance via telehealth, understand upfront that a follow-up in-person evaluation may be required as rules are finalized, and plan accordingly. Staying informed protects your access to medication and helps ensure your treatment is not interrupted by a regulatory surprise. Your telehealth provider should be transparent about these requirements; if they are evasive about compliance, consider that a red flag.
This article is for general education and reflects the situation as of early 2026. Telemedicine rules for controlled substances are changing frequently – verify the current status with the DEA and your prescriber. This is not legal or medical advice.
Sources
- Drug Enforcement Administration (DEA), Diversion Control Division – Telemedicine and controlled substance prescribing
- Federal Register – Temporary extensions of COVID-19 telemedicine flexibilities (including the fourth extension published December 2025 through December 31, 2026); Special Registrations for Telemedicine (proposed rule, January 2025); Expansion of Buprenorphine Treatment via Telemedicine (final rule, January 2025)
- Substance Abuse and Mental Health Services Administration (SAMHSA) – Buprenorphine and telehealth guidance
- Federation of State Medical Boards (FSMB) – State telemedicine and telehealth policies
- Ryan Haight Online Pharmacy Consumer Protection Act of 2008; Mainstreaming Addiction Treatment (MAT) Act